Takeda S, Takada S, Kojima T, Kinoshita K, Sakamoto S
Dept. of Obstetrics and Gynecology, Saitama Medical Center, Saitama Medical School.
Gan To Kagaku Ryoho. 1990 Sep;17(9):1929-31.
A 49-year-old woman with stage III ovarian cancer (undifferentiated adenocarcinoma), who refused combination chemotherapy for postoperative residual tumor, were successfully treated with daily oral etoposide in the outpatient clinic. The etoposide (50 mg/day) was first given orally and then a dose of etoposide was decreased to 25 mg/day because of alopecia and gastrointestinal toxicity. After seven months of treatment, the complete remission was confirmed by the second look laparotomy, and cytology of peritoneal surface revealed no signs of adenocarcinoma. This case suggests that daily oral etoposide therapy might be the alternative as a first-line and second-line chemotherapy of ovarian cancer in the outpatient clinic.
一名49岁患有III期卵巢癌（未分化腺癌）的女性，因拒绝接受术后残留肿瘤的联合化疗，在门诊接受了口服依托泊苷的成功治疗。最初口服依托泊苷（50毫克/天），后因脱发和胃肠道毒性将剂量减至25毫克/天。治疗七个月后，二次剖腹探查证实完全缓解，腹膜表面细胞学检查未发现腺癌迹象。该病例表明，门诊口服依托泊苷治疗可能作为卵巢癌一线和二线化疗的替代方案。
